Latest News

Ampio provides a Link to New Publication on the Mechanism of Action for Ampion™

Date: July 12, 2018 | READ MORE >

Ampio Reports New Publication on the Mechanisms of Action for Ampion™

Date: June 27, 2018 | READ MORE >

Ampio Provides Scientific Update and Links to Peer Review Publications

Date: June 5, 2018 | READ MORE >

Ampio Updates Regulatory and IP Activities

Date: May 29, 2018 | READ MORE >

Ampio Updates Scientific presentations and publications on Ampion™

Date: May 22, 2018 | READ MORE >

Ampio Provides Corporate Update

Date: May 14, 2018 | READ MORE >

The Pivotal Trial Results on Ampion™ (AP-003-C) Was Accepted for Publication in a Peer-Reviewed Medical Journal

Date: May 2, 2018 | READ MORE >

Ampio Updates Regulatory, Clinical and NYSE Activities

Date: April 12, 2018 | READ MORE >

Publication in Nature Biotechnology – “Low-molecular-weight albumin drug touted for severe osteoarthritis”

Date: April 11, 2018 | READ MORE >

Ampio Updates Regulatory and Clinical Activities

Date: April 3, 2018 | READ MORE >

Evidence for Delay of Total Knee Replacement (TKR) for Patients with Severe Osteoarthritis of the Knee Receiving Three Intra-articular (IA) Ampion™ Injections

Date: March 26, 2018 | READ MORE >

Ampio Pharmaceuticals Provides Corporate Update Following Conference Call

Date: March 16, 2018 | READ MORE >

Ampio Hosting Conference Call, Wednesday, March 7, 5:00 pm EST

Date: March 6, 2018 | READ MORE >

Ampio Update of J.P. Morgan Meeting Events and Disease Modification Discussions

Date: January 16, 2018 | READ MORE >

Ampio Presentation at J.P. Morgan Healthcare Conference made available to all Shareholders

Date: January 8, 2018 | READ MORE >

Ampio Pharmaceuticals Reports Positive Results for both Primary and Secondary Endpoints of Pivotal Phase 3 Trial of Ampion™ in Severe Osteoarthritis-of-the Knee (OAK)

Date: December 14, 2017 | READ MORE >

Ampio Pharmaceuticals Announces Engagement of LaVoieHealthScience for Integrated Public and Investor Relations

Date: November 30, 2017 | READ MORE >

Ampio Announces Publication of Ampion™ Treatment of Severe Osteoarthritis of the Knee as a Feature Article in Orthopedics Peer-Reviewed Journal

Date: November 22, 2017 | READ MORE >

Ampio Pharmaceuticals, Inc. Announces Continued Listing Plan Accepted by NYSE American

Date: November 16, 2017 | READ MORE >

Ampio Announces Start of Open Label Extension Study to Support Commercial Label of Repeat Administration of Ampion™ in Severe Osteoarthritis of the Knee

Date: November 15, 2017 | READ MORE >

Ampio Pharmaceuticals, Inc. Announces Closing of Registered Direct Offering

Date: October 18, 2017 | READ MORE >

Ampio Pharmaceuticals, Inc. Announces Pricing of Registered Direct Offering

Date: October 16, 2017 | READ MORE >

Ampio Announces Accepted Publication of Pooled Ampion™ Clinical Trial Results in Patients with Severe Osteoarthritis of the Knee

Date: October 12, 2017 | READ MORE >

Ampio Completes Enrollment of Patients in 12-Week Pivotal Trial

Date: September 18, 2017 | READ MORE >

Ampio Pharmaceuticals, Inc. Announces Annual Shareholder Meeting

Date: September 8, 2017 | READ MORE >

Ampio Pharmaceuticals, Inc. to Present at the 19th Annual Rodman & Renshaw Global Investment Conference

Date: September 7, 2017 | READ MORE >

Ampio Discloses Receipt of Notice from NYSE American and Has Until March 1, 2019, to Gain Compliance

Date: September 7, 2017 | READ MORE >

Ampio Announces the Allowance of a Composition and Methods Patent in the USA Using Ampion™ in Conjunction with Stem Cells

Date: August 8, 2017 | READ MORE >

Replay is available under our Investor tab, Presentation and Media

Date: July 14, 2017 | READ MORE >

Ampio Hosting Conference Call, Wednesday, July 12, 4:30 pm EDT

Date: July 6, 2017 | READ MORE >

Ampio Injects First Patient in Final Pivotal Clinical Trial for Ampion™ BLA

Date: June 22, 2017 | READ MORE >

Ampio Announces Appointment of Interim Chief Financial Officer

Date: June 13, 2017 | READ MORE >

Ampio Pharmaceuticals, Inc. Announces Closing of Registered Direct Offering

Date: June 7, 2017 | READ MORE >

Ampio Pharmaceuticals, Inc. Announces Pricing of Registered Direct Offering

Date: June 2, 2017 | READ MORE >

Ampion™ Human Macrophage Study Results Accepted for Presentation at the 2017 Annual AAST Meeting in Baltimore

Date: May 5, 2017 | READ MORE >

Ampio Initiates Pivotal Trial of Ampion™

Date: May 1, 2017 | READ MORE >

AMPIO PHARMACEUTICALS AMENDS WARRANT AGREEMENT

Date: March 28, 2017 | READ MORE >

Ampio Updates Intellectual Property and Regulatory Exclusivity Strategy to Support the Commercialization of Ampion™

Date: March 23, 2017 | READ MORE >

UPDATE – AMPIO PHARMACEUTICALS PROVIDES CORPORATE UPDATE

Date: March 22, 2017 | READ MORE >

Ampio Pharmaceuticals Provides Corporate Update

Date: March 20, 2017 | READ MORE >

Ampio Hosting Conference Call Tuesday, March 7, 4:30pm EST

Date: March 1, 2017 | READ MORE >

Ampio Receives Guidance from the FDA and Proposes a Path for Approval for Single-Injection Ampion™ for the Treatment of Pain Due to Severe Osteoarthritis of the Knee

Date: February 27, 2017 | READ MORE >

Reminder of Annual Meeting of Stockholders

Date: January 5, 2017 | READ MORE >

Ampio Updates Clinical and Regulatory Activity

Date: November 10, 2016 | READ MORE >

Ampio Announces Accepted Publication of the Clinical Trial Results of Its Oral Drug, Optina™, Treatment of Diabetic Macular Edema

Date: October 4, 2016 | READ MORE >

Ampio Updates Clinical and Regulatory Activity

Date: September 29, 2016 | READ MORE >

Ampio Reports Peer-Reviewed Publication on the Potential use of Ampion™ in New Clinical Indications

Date: September 8, 2016 | READ MORE >

Ampio Reports Additional Peer-Reviewed Publication on Ampion™

Date: August 30, 2016 | READ MORE >

Ampio Pharmaceuticals, Inc. Announces Pricing of Registered Direct Offering

Date: August 29, 2016 | READ MORE >

Ampio Updates Regulatory Status of AMPION™

Date: August 3, 2016 | READ MORE >

Ampio Hosting Conference Call Today, July 5, 4:30pm EST

Date: July 5, 2016 | READ MORE >

Ampio announces results of Ampion™ trials

Date: June 30, 2016 | READ MORE >

Ampio Launches Clinical Trial of AMPION™ for the Treatment of Osteoarthritis of the Hand

Date: May 10, 2016 | READ MORE >

Ampio Reports Additional Peer-Reviewed Publications on Ampion™

Date: May 3, 2016 | READ MORE >

Ampio Completes Enrollment in Pivotal Clinical Trial of AMPION™

Date: March 29, 2016 | READ MORE >

Ampio Clarifies ATM Program

Date: February 11, 2016 | READ MORE >

Ampio’s OptimEyes Study Results to be presented at The Association for Research in Vision and Ophthalmology (ARVO)

Date: January 26, 2016 | READ MORE >

Ampio Announces 2016 Corporate Update on Thursday, January 28, 4:30pm EST

Date: January 25, 2016 | READ MORE >

Ampio’s OptimEyes Study Results to be presented at World Ophthalmology Congress

Date: January 11, 2016 | READ MORE >

The NYSE Establishes January 5, 2016 as the Ex-Distribution Date for the Ampio Distribution of Aytu BioScience Stock to Ampio Shareholders

Date: December 1, 2015 | READ MORE >

Ampio Announces Investor Call on its Aytu BioScience Common Stock Distribution on Thursday, November 19, 4:15 p.m. EST

Date: November 18, 2015 | READ MORE >

Ampio Will Distribute Aytu BioSciences Stock to Ampio Shareholders of Record on December 1, 2015

Date: November 17, 2015 | READ MORE >

Ampio Intends to Distribute Aytu BioScience Stock to Ampio Shareholders

Date: November 2, 2015 | READ MORE >

Ampio Pharmaceuticals, Inc. Announces Updates On the Regulatory Path for FDA Approval of Optina™, an Oral Treatment for Diabetic Macular Edema (DME)

Date: October 14, 2015 | READ MORE >

AMPIO Receives Special Protocol Assessment (SPA) from the FDA and Commences Second Phase III pivotal trial of Ampion™

Date: September 22, 2015 | READ MORE >

Clinical Trial Design – AP-003-B (PIVOT) Study Synopsis

Date: September 22, 2015 | READ MORE >

Ampio Hosts Investor Call to Discuss Updates on Ampion™ and Optina™ (Audio Available)

Date: July 17, 2015 | READ MORE >

Ampio Announces Investor Call on Thursday, July 16, 4:30 p.m. EDT

Date: July 9, 2015 | READ MORE >

Ampio Pharmaceuticals Announces Additional Statistically Significant Study Results for Optina™ in the Treatment of Diabetic Macular Edema (DME)

Date: June 22, 2015 | READ MORE >

Ampio Pharmaceuticals Provides Information on the Formation and Significance of Aytu BioScience to Ampio Shareholders

Date: June 16, 2015 | READ MORE >

Ampio Pharmaceuticals Reports the Synergistic Effects of Ampion in the Treatment of Osteoarthritis of the Knee in Three Peer-reviewed Publications

Date: June 9, 2015 | READ MORE >

Ampio Pharmaceuticals Announces Update of STRIDE Study for the Investigation of Pain Associated with Osteoarthritis

Date: June 4, 2015 | READ MORE >

Ampio Pharmaceuticals Announces Positive Study Results on Optina for the Treatment of Diabetic Macular Edema

Date: May 21, 2015 | READ MORE >

Ampio Announces Top-Line Results of the Double-Blind Multiple Intra-Articular Injections (STRUT) Study of Ampion™ in Patients with Moderate to Severe Osteoarthritis of the Knee

Date: February 25, 2015 | READ MORE >

Ampio Updates Status of Clinical Trials and Manufacturing Facility

Date: November 12, 2014 | READ MORE >

Ampio Pharmaceuticals announces the FDA has issued a written response and accepted the Ampio plan for beginning production of Ampion™ in the new facility

Date: July 30, 2014 | READ MORE >

Ampio Receives FDA Confirmation that The Spring Study is Pivotal and Will Initiate the Final Pivotal Trial for Ampion™ Biological License Application (BLA)

Date: December 2, 2013 | READ MORE >

Ampio Pharmaceuticals, Inc. Announces Positive Results for Ampion in Osteoarthritis of the Knee Clinical Trial

Date: August 14, 2013 | READ MORE >